|
| Shire receives FDA approval for INTUNIV extended release tablets |
4 Sep 09, 09:24 |
|
| Shire plc, the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. |
| more |
|
